PFIZER INC (PFE) Form 8-K — Nov 3, 2026
Pfizer reported Q3 2026 revenues of $16.6 billion, roughly flat year-over-year, with reported diluted EPS of $0.56 and Adjusted diluted EPS of $0.87. Excluding COVID products Comirnaty and Paxlovid, revenues grew 7% operationally, and launched and acquired products grew 32% operationally, led by Eliquis (+25%), Padcev (+55%), and Lorbrena (+43%). Pfizer raised full-year 2026 guidance: revenue guidance was increased by $1.5 billion at the midpoint to $62.0-$64.0 billion, and Adjusted diluted EPS guidance was raised and narrowed to $2.95-$3.05 from $2.80-$3.00. Results absorbed a one-time $650 million Acquired IPR&D charge tied to the Innovent Biologics in-licensing deal (~$0.10 EPS impact).
Key figures
- Eps
- 0.56
- Revenue
- 16583000000
- Guidance
- FY2026 revenue raised to $62.0-$64.0B (from $60.5-$62.5B); Adjusted diluted EPS raised and narrowed to $2.95-$3.05 (from $2.80-$3.00)
- Net Income
- 3242000000
- Revenue Yoy
- relatively flat (~-$71M, -0.4%)
- R d invested 9m
- $8.3 billion
- Guidance revenue
- $62.0 to $64.0 billion
- Dividends paid 9m
- $7.3 billion ($1.29/share)
- Nine month revenue
- 46067000000
- Guidance adjusted eps
- $2.95 to $3.05
- Nine month net income
- 5681000000
- Adjusted diluted eps q3
- 0.87
- Non covid operational growth
- 7%
- Acquired iprd charge innovent
- $650 million (~$0.10 EPS impact)
- Remaining buyback authorization
- $3.3 billion
- Operational growth launched acquired products
- 32%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.